|
Name |
didymellanosine
|
Molecular Formula | C44H54N6O8 | |
IUPAC Name* |
28-[[9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]-1,22-dihydroxy-4,6,8,10,12,14-hexamethyl-2-oxa-24-azaheptacyclo[21.2.2.13,7.116,20.09,17.011,15.022,29]nonacosa-5,8,12,16,19,26-hexaen-25-one
|
|
SMILES |
CC1=CC2(C)C(=C(C)C3C4CC(C)CC(C)C4C4Oc5ccc(cc5)CC5(O)NC(=O)C(=C(O)C2C43)C5Nc2ncnc3c2ncn3C2OC(CO)C(O)C2O)C1C
|
|
InChI |
InChI=1S/C44H54N6O8/c1-18-11-19(2)27-25(12-18)28-22(5)31-21(4)20(3)13-43(31,6)32-29(28)37(27)57-24-9-7-23(8-10-24)14-44(56)38(30(35(32)53)41(55)49-44)48-39-33-40(46-16-45-39)50(17-47-33)42-36(54)34(52)26(15-51)58-42/h7-10,13,16-19,21,25-29,32,34,36-38,42,51-54,56H,11-12,14-15H2,1-6H3,(H,49,55)(H,45,46,48)/b35-30+/t18-,19+,21+,25-,26-,27-,28+,29+,32+,34-,36-,37-,38?,42-,43+,44-/m1/s1
|
|
InChIKey |
WKXRHPPDRVJMSP-MUNFTDNXSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 794.95 | ALogp: | 3.9 |
HBD: | 7 | HBA: | 13 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 204.3 | Aromatic Rings: | 11 |
Heavy Atoms: | 58 | QED Weighted: | 0.181 |
Caco-2 Permeability: | -5.625 | MDCK Permeability: | 0.00001050 |
Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.998 |
Human Intestinal Absorption (HIA): | 0.119 | 20% Bioavailability (F20%): | 0.021 |
30% Bioavailability (F30%): | 0.043 |
Blood-Brain-Barrier Penetration (BBB): | 0.019 | Plasma Protein Binding (PPB): | 96.81% |
Volume Distribution (VD): | 3.547 | Fu: | 3.17% |
CYP1A2-inhibitor: | 0.003 | CYP1A2-substrate: | 0.809 |
CYP2C19-inhibitor: | 0.041 | CYP2C19-substrate: | 0.42 |
CYP2C9-inhibitor: | 0.024 | CYP2C9-substrate: | 0.077 |
CYP2D6-inhibitor: | 0.083 | CYP2D6-substrate: | 0.023 |
CYP3A4-inhibitor: | 0.909 | CYP3A4-substrate: | 0.894 |
Clearance (CL): | 10.564 | Half-life (T1/2): | 0.008 |
hERG Blockers: | 0.158 | Human Hepatotoxicity (H-HT): | 0.502 |
Drug-inuced Liver Injury (DILI): | 0.983 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 1 | Maximum Recommended Daily Dose: | 0.969 |
Skin Sensitization: | 0.011 | Carcinogencity: | 0.029 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.002 |
Respiratory Toxicity: | 0.98 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003606 | 0.534 | D06IAR | 0.280 | ||||
ENC005366 | 0.534 | D0NI0C | 0.280 | ||||
ENC003773 | 0.484 | D06ACW | 0.250 | ||||
ENC003240 | 0.484 | D0B8SV | 0.247 | ||||
ENC005135 | 0.359 | D0XE1C | 0.244 | ||||
ENC005769 | 0.358 | D0B8UJ | 0.236 | ||||
ENC005766 | 0.352 | D0U3YU | 0.236 | ||||
ENC005768 | 0.345 | D0TG7I | 0.233 | ||||
ENC003137 | 0.344 | D0F2XQ | 0.233 | ||||
ENC005770 | 0.337 | D0Q2QU | 0.228 |